Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

DPX-Survivac

- PMLiVE

Genmab to expand oncology portfolio through $1.8bn ProfoundBio acquisition

The deal includes a next-generation ADC being evaluated as a treatment for ovarian cancer and other solid tumours

- PMLiVE

AbbVie’s Elahere granted full FDA approval for previously-treated ovarian cancer

The company recently gained access to the therapy through its $10.1bn acquisition of ImmunoGen

- PMLiVE

AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer

Approximately 7,400 new cases of the disease are diagnosed in the UK every year

- PMLiVE

AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition

The agreement grants the company access to FDA-approved ovarian cancer drug Elahere

EU flag

EC approves pharmaand’s Rubraca as advanced ovarian cancer maintenance treatment

An estimated 66,000 new cases of ovarian cancer are diagnosed in Europe each year

- PMLiVE

Kite and Arcellx expand cell therapy partnership in deal worth over $285m

The companies' existing CART-ddBCMA collaboration now covers lymphomas

- PMLiVE

Kite and Epic Bio announce cancer cell therapy collaboration agreement

The partnership centres around Epic Bio’s proprietary gene regulation platform

- PMLiVE

Novo Nordisk Foundation commits €127m for new cell therapy facility

The new facility will help accelerate treatments for people living with chronic diseases

- PMLiVE

Astellas invests $50m to support advancement of Poseida’s cancer cell therapy

The company will gain the first refusal to one of Poseida’s clinical stage programmes

- PMLiVE

New study shows AI model can identify where patients’ cancers originated

The predictions from OncoNPC could enable doctors to choose targeted cancer treatments

- PMLiVE

FDA approves CellTrans’ Lantidra as first cellular therapy to treat type 1 diabetes

The therapy is indicated for use in patients who are unable to meet their target blood glucose levels

Bayer symbol

Bayer and BlueRock announce positive early-stage results for Parkinson’s cell therapy

The progressive neurological disorder affects around ten million people worldwide

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links